ARS Pharmaceuticals(SPRY) - 2024 Q2 - Quarterly Results

Exhibit 99.1 ARS Pharmaceuticals Provides Business Highlights and Reports Second Quarter 2024 Financial Results neffy® (epinephrine nasal spray) New Drug Application (NDA) under review by FDA; discussions are ongoing to finalize labeling with FDA; PDUFA date in early October 2024 EURneffy® (adrenaline nasal spray) recommended for approval by EMA's CHMP; formal marketing authorization anticipated in the third quarter of 2024 Outpatient study of neffy for urticaria (hives) on track to initiate in the fourth q ...